Orphan designation: risvutatug rezetecan Treatment of pulmonary neuroendocrine carcinoma, 20/10/2025 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 14 April 2026 - 16:00

Orphan designation: risvutatug rezetecan Treatment of pulmonary neuroendocrine carcinoma, 20/10/2025 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3140

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters